Top 3 Growth Stocks With Earnings Growth Up To 63%

AI related exports helped lift China’s GDP growth to 4.5% in the latest quarter, even as parts of its economy stayed sluggish. That split world, where some sectors power ahead while others stall, rewards businesses that already grow fast and whose leaders have real skin in the game. This article walks through three rapid growers with heavy insider stakes pulled from our screener.

The three stocks highlighted here offer a compelling starting point if you want exposure to fast growing businesses where insiders are heavily invested alongside you. However, if you want the pick of this theme, these 371 high growth high conviction stocks are the best of the best.

Lasertec (TSE:6920)

Lasertec designs and sells semiconductor inspection and measurement equipment, with EUV mask and wafer inspection tools putting it squarely in the fast growth, high conviction theme. Almost all of its ¥230,485 million revenue comes from this equipment line, and the business is valued at about ¥3,696b.

Investors looking at fast growing stocks with committed leadership may find Lasertec interesting, because its EUV inspection systems are tied directly to advanced chip production. Analyst estimates currently indicate earnings may rise about 19% a year, and sentiment already appears to price in success while leaving limited room for disappointment if a single key assumption breaks.

To see how much is already priced in, review the DCF valuation analysis for Lasertec to gauge where expectations could be most exposed.

Micronics Japan (TSE:6871)

Micronics Japan focuses on semiconductor testing gear that fits the fast growing stocks with high insider ownership theme, with its probe card business generating about ¥84,868 million compared with ¥1,391 million from the TE segment. The company is valued at roughly ¥521.5 billion.

Micronics Japan is directly involved in the semiconductor testing build out. Insider backed expansion can reward patient holders, depending on how one unseen pressure plays out.

That hidden pressure matters, so review the 2 key rewards and 1 important major warning sign to see where Micronics Japan’s insider backing and growth ambitions could decouple from expectations.

CanSino Biologics (SEHK:6185)

CanSino Biologics develops, manufactures, and sells human vaccines in China, including its Ad5-nCoV inhalation COVID-19 shot and several Phase I programs that tie its growth story closely to vaccine R&D. The group generated about CN¥1.2b from human-use vaccine research and has a market value near HK$15.1b.

CanSino Biologics is closely linked to this high growth, insider aligned theme, with earnings forecast to climb quickly and new approvals like the Td5cp adolescent and adult booster adding fresh opportunities for commercial traction. However, one unresolved variable still has the power to reshape how that revenue translates into lasting profitability.

That profit question is exactly what the 5 key rewards and 2 important warning signs (1 is major!) reveals, showing where CanSino Biologics’ vaccine pipeline and insider alignment could accelerate or stall the story.

Seeking Fresh Alternatives Beyond Today?

Fresh breakout stories rarely stay under the radar for long. Momentum shifts fast and information decays before the crowd catches up. Scan these ideas while it matters and consider them early in your research process.

• Target resilient cash generators with strong balance sheets by running a focused search through the list of solid balance sheet and fundamentals (22 results) curated from businesses built to handle shocks.
• Look for potential income opportunities by tracking candidates in the 29 dividend fortresses while payout strength and momentum still align.
• Review the build out of critical digital rails by considering infrastructure-focused opportunities highlighted in the 42 power grid technology and infrastructure stocks before capital fully prices in their role.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com